Clinical Trials Logo

Clinical Trial Summary

This multicentre randomised controlled trial aimed to reduce the visual discomfort that patients implanted with trifocal diffractive intraocular lenses may experience after surgery. To this end, a visual training software (Optictrain) was developed in which Gabor patches were presented to the patient on a hand-held electronic device. Patients who met all inclusion criteria and consented to participate underwent half an hour of visual training per day for a period of 20 consecutive days remotely on a colourimetrically characterised Samsung Galaxy Tab A device on which the Optictrain software (n=30) or a placebo software (n=30), respectively, was pre-installed. Corrected and uncorrected near, intermediate and distance visual acuity (VA) and mesopic near and distance contrast sensitivity (CS) were measured monocularly and binocularly at two visits: during the first postoperative week (V0) and after 20 days of visual training with the assigned software (V1). The statistical analysis of the results obtained in the study has not yet been carried out.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Blindness
  • Visual Acuity Reduced Transiently
  • Visual Disturbances and Blindness

NCT number NCT04985097
Study type Interventional
Source Increase-Tech
Contact
Status Completed
Phase N/A
Start date September 1, 2018
Completion date July 20, 2021

See also
  Status Clinical Trial Phase
Completed NCT04703231 - Comparison of Ocular Findings in Patients Between Surgical and Natural Menopause
Completed NCT04724525 - Changes in Power and Cylinder Axis of Toric Soft Contact Lenses (LKL) N/A
Completed NCT01244334 - Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. Phase 4
Terminated NCT03409185 - The Incidence of Glistenings in the 2017 Intraocular Lenses Made by Alcon and Abbott Medical Optics N/A
Terminated NCT02665689 - Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab Phase 4